AIM: To discuss the effects of preoperative vitreous cavity injection of ranibizumab on 25G minimally invasive vitreoretinal surgery(VRS)in patients with proliferative diabetic retinopathy(PDR).

METHODS: From February 2013 to December 2015, 74 patients with PDR received VRS(82 eyes)were retrospectively analyzed. Patients were divided into VRS + IVR group and VRS group according to preoperative VRS treatment. VRS+IVR group: preoperative injection of ranibizumab(10mg / mL)at 3-5d before operation; VRS group: VRS only. We recorded VRS operation time, filling situation, iatrogenic retinal hole and so on.

RESULTS: The operation time and coagulation times of VRS+IVR group were significantly lower than VRS group. The two groups in operation time and coagulation times were statistically significant(all P<0.05). In the VRS+IVR group, the number of cases of iatrogenic retinal hole and the use of silicone oil were lower than those of VRS group, the difference between the two groups was statistically significant(P<0.05). While the use number of C₃F₈ and perfusion fluid were not statistically significant(P>0.05). In VRS-IVR group within 3mo after operation, 4 eyes appeared to vitreous body hematocele, VRS group was 13 eyes, the difference was statistically significant(χ²=4.966, P<0.05).

CONCLUSION: PDR patients with 25G minimally invasive VRS with preoperative therapy can reduce postoperative ocular bleeding, rate of retinal injury and silicone oil filling, shorten the operation time, the incidence rate and improve the success rate of surgery and reduce eye bleeding, postoperative complications such as adhesion.